Abstracts

Poster Presentation Dates

All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.

Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).

#	Title	Authors	Category	Keywords
O63	Gastric toxicity associated with PD-1 blockade therapy revealed by Multiplexed Ion Beam Imaging	Selena Ferrian, PhD; Theodore S. Nowicki, MD, PhD; David W. Dawson; Alex Baranski; John Glaspy, MD; Antoni Ribas, MD, PhD; Michael Angelo, MD, PhD;	Immunotherapy Toxicities	Autoimmunity; Checkpoint blockade; Inflammation; Systems biology
O64	Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease	Hamzah Abu-Sbeih, MD; David Faleck; Biagio Ricciuti, MD; Robin Mendelsohn; Abdul Rafeh Naqash, MD; Justine V. Cohen, DO; MacLean C. Sellars; Aanika Balaji; Guy Ben-betzalel; Ibraheim Hajir; Jiajia Zhang, MD, MPH; Mark Awad, MD PhD; Giulia Leonardi; Douglas B. Johnson, MD, MSCI; David J. Pinato, MD, MRes, PhD; Dwight Owen; Sarah A. Weiss, MD; Giuseppe Lamberti, MD; Mark Lythgoe; Lisa Manuzzi; Christina Arnold; Wei Qiao, PhD; Jarushka Naidoo, MD; Gal Markel; Nick Powell; Sai-Ching J. Yeung, MD, PhD; Elad Sharon, MD, MPH; Michael Dougan, MD, PhD; Yinghong Wang, MD, PhD;	Immunotherapy Toxicities	Autoimmunity; Checkpoint blockade; Immune suppression; Immune toxicity; Inflammation
P708	Real world evidence of patient clinical profiles with advanced solid tumor malignancies receiving immune checkpoint inhibitors to investigate potential predictors for immune-related adverse events.	Stephanie Berg, DO; Joseph I. Clark, MD; Jose Guevara; Elizabeth Elliott, DO; Stephanie Berg, DO; Stephanie Berg, DO; Michael Wesolowski; Blaine Knox, MD; Daniel Linden, DO; Courtney Wagner, MD;	Immunotherapy Toxicities	Biomarkers; Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors
P709	Immunotherapy Adverse Events Predict Treatment Response	Diana V. Maslov; Katherine Thomas, MD, MS; Victoria Simenson, MD; Caitlin Sullivan, MD; Alaa Mohammed, MPH; Jessica Boyce; Jonathan Lu, MD; John Kucharczyk, MD; Marc R. Matrana;	Immunotherapy Toxicities	Checkpoint blockade; Immune tolerance; Immune toxicity; Solid tumors; Targeted therapy
P710	Immune Checkpoint Inhibitors increase the risk of Hypothyroidism in Patients with Primary Head and Neck Cancer Compared to Other Cancers	Omar A. Alaber, MD; Apoorva K. Chandar; Prateek Mendiratta, MD; Monaliben Patel, MD; Chris J. Hoimes, MD; Pierre Lavertu, MD; Ankit Mangla, MD	Immunotherapy Toxicities	Checkpoint blockade; Epidemiology; Immune toxicity; Radiotherapy; Solid tumors; Targeted therapy
P711	Single-Center Analysis of Safety and Efficacy of Immune Checkpoint Inhibitors (ICI) in Non-Hematologic Malignancies: Effects of Age and Eosinophilia	Justin T. Moyers, MD; Dhanu Desai; Jasmine Mitchell; Jeffrey Ahn; Steven Hardin; Mie Mie Thinn;	Immunotherapy Toxicities	Checkpoint blockade; Immune monitoring; Immune toxicity
P712	Conditional immune toxicity rate with immune checkpoint inhibitors	Pier Vitale Nuzzo, MD, PhD; Gregory Russell Pond, M.Sc, PhD; Amin Nassar, MD; Sarah Abou Alaiwi, MD; Ronan Flippot, MD; Catherine Curran; Kerry Kilbridge, MD; Xiao Wei, MD; Bradley Mcgregor, MD; Lauren Harshman, MD; Toni K. Choueiri; Guru Sonpavde, MD;	Immunotherapy Toxicities	Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; Targeted therapy
P714	Immunological features of immune-related adverse events during anti-PD-1/PD-L1 immune checkpoint inhibition	Meghali Goswami, MPhil; Gege Gui; Katherine E. Lindblad; Jaydira Del Rivero, MD; Jennifer Marte, BS MD; Pradeep K. Dagur, PhD; Christin B. Destefano, MD; Julie Thompson, RN; Bogdan Popescu, MD; Laura Dillon, PhD; Cheryl D. Johnson; Steven J. Soldin, PhD; Catherine Lai, MD, MPH; James L. Gulley, MD, PhD, FACP; Christopher S. Hourigan, MD, PhD;	Immunotherapy Toxicities	Autoimmunity; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune toxicity; Leukemia/Lymphoma; T cell
P715	Strategies to mitigate immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer	Célia Jacoberger-Foissac, PhD; Stephen J. Blake; Célia Jacoberger-Foissac, PhD; Jing Liu; Stacey Allen; Juming Yan; Heidi Harjunpaa; Mark J. Smyth; Michele W. Teng, PhD;	Immunotherapy Toxicities	Antibody; Autoimmunity; Cytokine; Immune suppression; Immune toxicity; Regulatory T cell (Treg cell); Solid tumors
P716	An In Vivo PBMC Humanized Mouse Model for Determining Checkpoint and Bispecific Antibody Treatment Related Cytokine Release Syndrome	Chunting Ye; Mingshan Cheng; Michael Brehm; Dale Greiner; Leonard Shultz; James Keck, PhD;	Immunotherapy Toxicities	Checkpoint blockade; Cytokine; Immune toxicity
P717	Involvement of IL17 in a case of fatal neuroendocrine toxicity associated with dual immune checkpoint blockade	Luca Mazzarella, MD PhD; Silvia Giugliano; Paolo D'Amico; Carmen Belli; Bruno Duso; Giuseppe Curigliano, MD, PhD; Maria Rescigno, MD, PhD; Luca Mazzarella, MD PhD;	Immunotherapy Toxicities	Checkpoint blockade; Cytokine; Dendritic cell; Immune toxicity
P718	A case of dual-mechanism hematologic immune-related adverse event in a patient with metastatic melanoma treated with combined nivolumab and ipilimumab	Daniel J. Olson, MD; Melissa Tjota, MD, PhD; Padma Rajagopal, MD; Girish Venkataraman, MD; Jason J. Luke, MD, FACP; Thomas F. Gajewski, MD, PhD;	Immunotherapy Toxicities	Autoimmunity; Checkpoint blockade; Immune toxicity
P719	CD8+ Tcell integrin α4β7expression: a potential predictor of severity and steroid sensitivity in checkpoint inhibitor induced colitis	Anna C. Olsson-Brown, MBChB (Hons), BSc (Hons); Joseph Sacco, MSc, MBChB, MRCP, Ph; Sandra CP. Cachinho; Carol Jolly; Vanessa Fontana; Rosemary Lord; Mark Coles; Munir Pirmohamed;	Immunotherapy Toxicities	Immune toxicity; Inflammation; Solid tumors; T cell
P720	The use of in vitro assays to reduce the risk of unwanted immunogenicity	Amin Osmani; Thibault Jonckheere; Sofie Pattijn; Mayuko Oh; Thibaut Janss;	Immunotherapy Toxicities	Dendritic cell; Immune suppression; Immune tolerance; Immune toxicity; Monocyte/Macrophage; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell
P721	Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis	Hamzah Abu-Sbeih, MD; Lauren N. Herrera; Tenglong Tang, MD; Mehmet Altan; Anne-Maria P. Chaftari; Pablo C. Okhuysen; Robert Jenq, MD; Yinghong Wang, MD, PhD;	Immunotherapy Toxicities	Autoimmunity; Checkpoint blockade; Immune toxicity; Inflammation; Microbiome
P722	Opportunistic Infection Outcomes in Patients Receiving Corticosteroids for Immune Checkpoint Inhibitor Toxicity	Michael R. Cook, MD; Michael B. Atkins, MD;	Immunotherapy Toxicities	Checkpoint blockade; Immune suppression; Immune toxicity
P723	Interleukin-6 blockade to de-couple CTLA-4 blockade colitis from anti-tumor efficacy	Yared Hailemichael, PhD; Daniel H. Johnson, MD; Wai C. Foo; Kenneth R. Hess, BS, MS, PhD; Cara Haymaker, PhD; Chantal M. Saberian, MD; Salah E. Bentebibel; Elizabeth Burton; Yinghong Wang, MD, PhD; Scott Woodman; Patrick Hwu, MD; Adi Diab, MD;	Immunotherapy Toxicities	Autoimmunity; Checkpoint blockade; Chemokine; Cytokine; Immune toxicity; Inflammation; Monocyte/Macrophage; Myeloid cells; T cell; Tumor infiltrating lymphocytes (TILs)
P724	Analysis of healthcare provider management of immune-related adverse events and concordance with NCCN Guidelines®	Megan Cartwright, PhD; Krista Marcello, BA; Jillian L. Scavone, PhD; Kevin L. Obholz, PhD; Timothy A. Quill, PhD; John A. Thompson;	Immunotherapy Toxicities	Autoimmunity; Checkpoint blockade; Immune toxicity
P725	Clinical features of immune checkpoint inhibitor-related adrenal insufficiency: a retrospective analysis	Qinwen Zhou, MD; Sandip P. Patel, MD; Qinwen Zhou, MD; Vala Hamidi; Qinwen Zhou, MD;	Immunotherapy Toxicities	Autoimmunity; Checkpoint blockade; Immune monitoring; Immune toxicity; Solid tumors